ACArthur Ribeiro Cenci

Arthur Ribeiro Cenci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arthur Ribeiro Cenci has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Aldo Sena de Oliveira

    Gulbenkian Institute for Molecular Medicine (GIMM), Faculty of Medicine, University of Lisbon, Lisbon, 1649-028, Portugal

    3 shared publications
  • Adriano D. Andricopulo

    Center for Research & Innovation in Biodiversity & Drug Discovery, Institute of Physics of Sao Carlos, University of Sao Paulo, São Carlos-SP, Brazil

    1 shared publication
  • Angelica Justino

    Department of Chemistry, Federal University of Santa Catarina, Florianópolis-SC, Brazil

    1 shared publication
  • Antonio Luiz Braga

    Department of Chemistry Federal University of Santa Catarina – UFSC Florianópolis Santa Catarina 8040‐900 Brazil

    1 shared publication
  • Igor Vinícius de França

    Department of Exact Sciences and Education, Federal University of Santa Catarina – Campus of Blumenau, Rua João Pessoa, 2750 – Velha, Blumenau – SC, 89036-256, Brazil

    1 shared publication
  • Kerolain F. Teixeira

    Department of Exact Sciences and Education, Federal University of Santa Catarina, Rua João Pessoa 2514 Bairro Velha, Blumenau-SC, 89036-004, Brazil

    1 shared publication

Latest Publications

  • Chalcone Derivatives as Antibacterial Agents: An Updated Overview

    by Aldo S. de Oliveira, Arthur R. Cenci, Lucas Gonçalves, Maria Eduarda C. Thedy, Angelica Justino, Antônio L. Braga, Lidiane Meier

    Background: The indiscriminate use of antibiotics brings an alarming reality: in 2050, bacterial resistance could be the main cause of death in the world, resulting in the death of 10 million people, according to the World Health Organization (WHO). In this sense, to combat bacterial resistance, several natural substances, including chalcones, have been described in relation to antibacterial, representing a potential tool for the discovery of new antibacterial drugs. Objective: The objective of this study is to perform a bibliographic survey and discuss the main contributions in the literature about the antibacterial potential of chalcones in the last 5 years. Methods: A search was carried out in the main repositories, for which the publications of the last 5 years were investigated and discussed. Unprecedented in this review, in addition to the bibliographic survey, molecular docking studies were carried out to exemplify the applicability of using one of the molecular targets for the design of new entities with antibacterial activity. Results: In the last 5 years, antibacterial activities were reported for several types of chalcones, for which activities were observed for both gram-positive and gram-negative bacteria with high potency, including MIC values in the nanomolar range. Molecular docking simulations demonstrated important intermolecular interactions between chalcones and residues from the enzymatic cavity of the enzyme DNA gyrase, one of the validated molecular targets in the development of new antibacterial agents. Conclusion: The data presented demonstrate the potential of using chalcones in drug development programs with antibacterial properties, which may be useful to combat resistance, a worldwide public health problem.


  • Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies

    by Valkiria Machado, Arthur R. Cenci, Kerolain F. Teixeira, Larissa Sens, Tiago Tizziani, Ricardo J. Nunes, Leonardo L. G. Ferreira, Rosendo A. Yunes, Louis P. Sandjo, Adriano D. Andricopulo, et al.

    Alzheimer's disease (AD) is a neurodegenerative disease that is characterized as the main dementia in the elderly. Eighteen pyrazolines were synthesized and evaluated for their inhibitory effects against acetylcholinesterase (AChE) in vitro. Possible interactions between pyrazolines and the enzyme were explored by in silico experiments. Compound 2B of the series was the most active pyrazoline with an IC50 value of 58 nM. Molecular docking studies revealed two important π–π interactions with residues Trp 286 and Tyr 341. A correlation between the HOMO-1 surface and AChE inhibition was observed. ADMET assays demonstrated a good profile for compound 2B. From the abovementioned findings, a new avenue of compound 2B analogues could be explored to develop anti-AD agents.


  • Witches, potions, and metabolites: an overview from a medicinal perspective

    by Luana Canzian Llanes, Nathalia Biazotto Sa, Arthur Ribeiro Cenci, Kerolain Faoro Teixeira, Igor Vinícius de França, Lidiane Meier, Aldo Sena de Oliveira

    In this review we present the bioactive compounds of two classic potions: love potion and sleeping potion. This review also includes details on the presence of these bio-active molecules in current medicine and their effects.